Life Sciences Nucleic Acid Sequencing Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Nucleic Acid Sequencing Platforms
1.1 - About Life Sciences Nucleic Acid Sequencing Platforms sector
Companies in the Life Sciences Nucleic Acid Sequencing Platforms category design and supply instruments, chemistries, automation, and analytics to sequence DNA and RNA at scale. They enable high-throughput genomic analysis for research, translational medicine, and diagnostics, reducing turnaround times and cost per sample while improving accuracy and reproducibility. Strategic buyers in this space typically offer integrated hardware, reagents, and software to support end‑to‑end sequencing workflows.
These vendors deliver high-throughput sequencers and compact benchtop systems alongside single-cell and long-read modalities. They provide library preparation kits and optimized sequencing chemistries, plus automated sample preparation and liquid handling to improve consistency. Their software spans bioinformatics pipelines for alignment, variant calling, de novo assembly, and expression analysis, with cloud or on‑prem data management, quality control, and reporting, and they integrate with LIMS and validation tools for regulated clinical workflows.
They serve biopharma R&D teams, clinical genomics and molecular diagnostics labs, and academic or hospital core facilities. Buyers achieve higher throughput and scalability, lower cost per genome or transcriptome, faster turnaround from sample to report, and improved sensitivity and accuracy in variant detection. The platforms also strengthen data governance, auditability, and regulatory compliance, supporting validated workflows for oncology, rare disease, infectious disease, and translational research programs.
2. Buyers in the Life Sciences Nucleic Acid Sequencing Platforms sector
2.1 Top strategic acquirers of Life Sciences Nucleic Acid Sequencing Platforms companies
PacBio
- Description: Provider of long-read SMRT and short-read SBB DNA sequencing solutions, including instruments, consumables and reagent kits that enable real-time single-molecule analysis to resolve genetically complex research, clinical and industrial problems for academic, governmental, healthcare and commercial laboratories worldwide.
- Key Products:
- Revio System: Production-scale HiFi long-read sequencer using SPRQ chemistry, delivers up to 120 Gb per SMRT Cell and runs four cells concurrently, requiring only 500 ng input and offering on-instrument 6mA methylation calling for cost-effective large projects
- Vega System: Benchtop HiFi long-read platform delivering 60 Gb per SMRT Cell with single-cell configuration, user-friendly interface and fast 12–24 h runs, letting labs generate complete genomes, transcriptomes and epigenomes in-house
- Onso System: Short-read sequencer powered by sequencing-by-binding chemistry that achieves 90 % Q40 accuracy—15× lower error than SBS—enabling sensitive rare-variant detection, low-complexity region analysis and reduced sequencing depth
- HiFi Long-Read Sequencing: Service producing 99.9 % accurate long reads that detect SNPs, indels
- STRs and structural variants while phasing haplotypes in difficult genomic regions without sacrificing read length.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Nucleic Acid Sequencing Platforms sector
M&A buyer group 1: Genomics
Neogen
- Type: N/A
- Employees: ●●●●●
- Description: Provider of food safety and quality assurance solutions for the pet-food sector, offering mycotoxin, pathogen, sanitation and allergen tests, environmental monitoring with microbiome analysis and analytics, plus verification tools, biosecurity, vector control and companion animal health products.
- Key Products:
- Environmental Monitoring Solutions: Provides Salmonella and ATP tests, analytic software, metagenomic microbiome analysis and biosecurity tools to strengthen facility-wide safety programs and enable rapid, data-driven contamination control
- Mycotoxin Testing Kits: Easy-to-use, fast and accurate kits that detect multiple mycotoxins, integrate seamlessly into safety programs and are supported by reference materials, proficiency testing and 24/7 assistance
- Vector Control Solutions: Broad portfolio of rodenticides and insecticides that follow a four-step prevention, identification, execution and monitoring program to eliminate disease-carrying pests in operations
- Companion Animal Health Products: Includes PanaKare Plus supplements for exocrine pancreatic insufficiency and RenaKare potassium supplementation, supporting specific nutritional needs of cats and dogs.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Nucleic Acid Sequencing Platforms sector
3.1 - Buyout funds in the Life Sciences Nucleic Acid Sequencing Platforms sector
2.2 - Strategic buyer groups for Life Sciences Nucleic Acid Sequencing Platforms sector
4 - Top valuation comps for Life Sciences Nucleic Acid Sequencing Platforms companies
4.2 - Public trading comparable groups for Life Sciences Nucleic Acid Sequencing Platforms sector
Valuation benchmark group 1: Clinical and Molecular Diagnostics Companies
Labcorp
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of comprehensive clinical laboratory and drug development services, harnessing science for human good with a wide range of diagnostic tests, specialty testing services, and research support globally.
- Key Products:
- Diagnostic Testing: Wide range of diagnostic tests for various conditions
- Specialty Testing: Advanced gene-based and esoteric testing
- Drug Development Services: Comprehensive services for drug development and clinical trials
- Health Screenings: Wellness, pediatric, COVID-19 antibody testing
- Labcorp OnDemand: At-home test kits and monitoring solutions